Q1 2026 earnings update

Crinetics Pharmaceuticals (CRNX) has drawn investor attention after reporting Q1 2026 results, with revenue of US$10.73 million compared with US$0.361 million a year earlier, alongside a wider net loss of US$127.85 million.

The stock has pulled back recently, with a 1-day share price return of a 4.02% decline and a 30-day share price return of a 7.54% decline. However, the 1-year total shareholder return of 17.70% and 5-year total shareholder return of 118.61% point to a stronger longer-term story.

If Q1 results have you reassessing growth opportunities in healthcare, it could be a good moment to look across the sector using our screener of 32 healthcare AI stocks.

With the stock down over the past quarter but still showing stronger multi year returns, and with analysts’ targets and intrinsic value models implying a wide gap to the current US$36.77 price, is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 55.4% Undervalued

Crinetics Pharmaceuticals' most followed narrative places fair value at $82.43 per share, well above the recent $36.77 close. This frames a wide valuation gap in the context of a high growth, loss making biopharma.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Growing focus on chronic symptom control and quality of life in rare endocrine diseases, supported by PALSONIFY’s label that highlights both biochemical and symptom control, can support physician preference and patient driven demand, which may help sustain prescription volumes and future earnings.

Want to see what kind of revenue curve and margin shift sits behind this valuation gap? The core narrative leans on aggressive top line expansion, improving profitability and a premium earnings multiple usually reserved for standout growth stories.

Result: Fair Value of $82.43 (UNDERVALUED)

However, you also need to weigh early PALSONIFY launch uncertainty and the risk of higher than expected cash use that could eventually lead to shareholder dilution.

Another angle on value

The SWS DCF model points to a fair value of US$432.31 per share, far above the recent US$36.77 price. This comparison presents Crinetics Pharmaceuticals as heavily undervalued. With such a wide gap between cash flow based value and market pricing, how comfortable are you with the assumptions that drive it?

Next Steps

Mixed signals on value and risk so far? Take a moment now to review the full data and evaluate the balance of 2 key rewards and 1 important warning sign

Looking for more investment ideas?

Before you move on, consider giving yourself a chance to spot fresh opportunities across the market that could complement or contrast with your view on Crinetics Pharmaceuticals.

• Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations using the 50 high quality undervalued stocks.
• Prioritise resilience by checking out the 66 resilient stocks with low risk scores, focused on businesses with steadier risk profiles that may suit a more defensive approach.
• Get ahead of the crowd by reviewing the screener containing 22 high quality undiscovered gems and see which lesser known stocks pass rigorous fundamental filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.